alpha-MSH: The Master Peptidergic Regulator

Alpha-melanocyte-stimulating hormone (α-MSH) represents one of the most versatile and evolutionary conserved peptide signaling molecules in vertebrate physiology. Synthesized through the targeted post-translational cleavage of pro-opiomelanocortin, this tridecapeptide orchestrates an extraordinary spectrum of biological processes ranging from cutaneous photoprotection to the central regulation of energy balance and immune suppression. An exhaustive understanding of α-MSH illuminates critical junctions where neurobiology, endocrinology, metabolic science, and immunology converge.

Alpha-Melanocyte-Stimulating Hormone (α-MSH)

1. Concise Definition

Alpha-melanocyte-stimulating hormone (α-MSH) is an endogenous peptide hormone consisting of 13 amino acids, derived from the enzymatic cleavage of the precursor polypeptide pro-opiomelanocortin (POMC). It acts as a primary agonist across multiple subtypes of the G-protein coupled melanocortin receptor family, exerting profound physiological control over melanogenesis, systemic energy homeostasis, and anti-inflammatory cascades.

Within the central nervous system, α-MSH serves as a pivotal anorexigenic neuropeptide produced predominantly by POMC neurons localized in the arcuate nucleus of the hypothalamus. In peripheral tissues, it functions as a paracrine and autocrine mediator produced by keratinocytes, immune cells, and intermediate pituitary cells, directly influencing skin pigmentation, mucosal host defense, and immune tolerance.

2. Etymology & Linguistic Origin

The term “alpha-melanocyte-stimulating hormone” reflects both classical biochemical nomenclature and descriptive physiological observation. The prefix “alpha” (α) derives from the first letter of the Greek alphabet (αˡλφα), utilized in biochemistry to denote the primary or first-discovered isoform among related molecular variants, distinguishing it from beta-MSH (β-MSH) and gamma-MSH (γ-MSH).

The root “melanocyte” combines the Ancient Greek mélas (μέλας, meaning “black” or “dark”) and kýtos (κύτος, meaning “hollow vessel” or “cell”). The descriptor “stimulating” stems from the Latin stimulare (“to goad, spur, or incite”), and “hormone” originates from the Greek hormon (óρμών), the present participle of horman (“to set in motion, urge on”). Historically, the phrase entered scientific literature in the mid-twentieth century when endocrinologists isolated pituitary secretions capable of dispersing pigment granules within amphibian dermal melanophores.

3. Pronunciation & Grammatical Form

The standardized international pronunciation of alpha-MSH is transcribed phonetically as /æl.fə εm.εs.eɪtʃ/ or fully articulated as /æl.fə məˈlæn.oʊ.saɪt ˈstɪm.jə.leɪ.tɪŋ ˈhɔːr.moʊn/. In scientific literature, it functions as a compound noun phrase, commonly abbreviated as α-MSH (with the Greek letter alpha or the spelled-out prefix “alpha-”).

Grammatically, the term functions as an uncountable mass noun when referring to the biochemical substance itself (e.g., “α-MSH induces melanogenesis”) and as a countable noun when referring to specific synthetic analogs, fragments, or molecular species (e.g., “modified α-MSHs exhibit prolonged half-lives”). The standard amino acid sequence is conventionally represented as Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂, reflecting essential N-terminal acetylation and C-terminal amidation modifications.

4. Detailed Conceptual Explanation

At its biochemical foundation, α-MSH is an ancient signaling peptide whose structural core has been conserved across hundreds of millions of years of vertebrate evolution. The molecule shares an identical 13-amino-acid sequence with the N-terminal segment of adrenocorticotropic hormone (ACTH_1–13). The conversion of POMC into α-MSH requires sequential processing by prohormone convertases, specifically prohormone convertase 1/3 (PC1/3) and prohormone convertase 2 (PC2). PC1/3 first cleaves POMC into ACTH and β-lipotropin, after which PC2 cleaves ACTH to yield ACTH_1–17. Carboxypeptidase E subsequently removes basic amino acids to generate ACTH_1–13, which then undergoes N-terminal acetylation by peptide α-N-acetyltransferase and C-terminal amidation by peptidylglycine α-amidating monooxygenase (PAM) to achieve full biological potency.

The biological actions of α-MSH are mediated through its interaction with the melanocortin receptor (MCR) family, a group of five rhodopsin-like class A G-protein coupled receptors designated MC1R through MC5R. Alpha-MSH exhibits pronounced affinities for MC1R, MC3R, MC4R, and MC5R, while exhibiting negligible affinity for MC2R, which selectively binds intact ACTH. The tetrapeptide sequence His-Phe-Arg-Trp (residues 6–9) represents the pharmacophore required for receptor binding and downstream signal transduction. Binding of α-MSH to its receptors generally couples to the Gα_s protein, activating adenylate cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP), and triggering downstream protein kinase A (PKA) pathways.

In cutaneous biology, α-MSH acts via MC1R on epidermal melanocytes. Exposure to ultraviolet (UV) radiation triggers DNA damage in basal keratinocytes, inducing p53-dependent transcription of POMC. Keratinocytes subsequently secrete α-MSH, which binds MC1R on adjacent melanocytes. The resulting elevation of cAMP activates microphthalmia-associated transcription factor (MITF), driving transcription of tyrosinase, TRP-1, and TRP-2. This cascade shifts melanin synthesis from red/yellow pheomelanin to black/brown eumelanin, offering photoprotection against future ultraviolet mutagenesis.

Centrally, α-MSH functions as a critical catabolic neuropeptide within the central melanocortin circuit. Leptin released by white adipose tissue and insulin secreted by pancreatic beta cells stimulate POMC-expressing neurons within the hypothalamic arcuate nucleus. These neurons project axons to secondary target areas, notably the paraventricular nucleus of the hypothalamus (PVN), releasing α-MSH. In the PVN, α-MSH engages MC4R and MC3R, activating neural networks that potently suppress food intake while increasing basal metabolic rate and adaptive thermogenesis through sympathetic nervous system outflow. When this pathway is disrupted, hyperphagic severe obesity inevitably ensues.

Beyond pigmentary and metabolic roles, α-MSH possesses profound immunomodulatory and anti-inflammatory properties. Operating via MC1R and MC3R expressed on monocytes, macrophages, dendritic cells, and endothelial cells, α-MSH suppresses the nuclear translocation of nuclear factor kappa B (NF-κB). Consequently, it downregulates the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6), while concurrently stimulating anti-inflammatory mediators such as interleukin-10 (IL-10). These pathways maintain immune privilege in delicate microenvironments like the anterior chamber of the eye and the central nervous system.

5. Historical Development

The discovery and functional characterization of α-MSH parallel the development of modern peptide endocrinology over the course of the twentieth century. In the early 1910s and 1920s, independent investigators Philip E. Smith and Bennet M. Allen demonstrated that hypophysectomy in amphibian tadpoles resulted in stark epidermal blanching, an effect that could be reversed by grafting pituitary tissue or administering crude pituitary extracts. These initial experiments demonstrated that the pituitary gland produced a substance capable of dispersing dark melanin granules within dermal melanophores, initially named “intermedin” due to its apparent localization in the intermediate lobe (pars intermedia) of the pituitary.

By the mid-1950s, rapid advancements in protein chromatography and amino acid sequencing allowed researchers to isolate and characterize this active principle. In 1955, Aaron B. Lerner and his colleagues at Yale University successfully purified and determined the complete 13-amino-acid primary structure of pig α-MSH. Soon thereafter, Choh Hao Li and collaborators confirmed the precise peptide sequence, noting its structural identity with the N-terminal tridecapeptide of ACTH. These discoveries proved that smaller, functionally distinct hormonal messengers could share structural homology with larger pituitary peptides.

A revolutionary conceptual leap occurred during the late 1970s through the work of Edward Herbert, Richard Mains, and Betty Eipper, who cloned and characterized the polyprotein pro-opiomelanocortin (POMC). This breakthrough established that ACTH, α-MSH, β-endorphin, and lipotropins originated from a single large precursor gene subjected to tissue-specific enzymatic processing. In the 1990s, the molecular cloning of the five melanocortin receptors by Roger Cone, Kathleen Mountjoy, and Ira Gantz provided the precise structural framework needed to understand how α-MSH exerted radically divergent effects in the skin, brain, and immune system. Subsequent genetic knockouts in rodents and identification of human MC4R mutations in the late 1990s established α-MSH as the central regulator of mammalian adiposity.

6. Theoretical Foundations

The physiological operation of α-MSH is best framed within three major theoretical paradigms: the dual-center model of homeostatic energy balance, the melanocortin rheostat hypothesis, and the neuro-immuno-cutaneous axis model.

Within the homeostatic energy balance paradigm, α-MSH functions as an indispensable catabolic effector. Energy balance regulation relies on an antagonistic, push-pull architecture in the hypothalamic arcuate nucleus. When energy stores are replete, high circulating leptin levels stimulate POMC neurons to release α-MSH, while simultaneously repressing adjacent neurons producing agouti-related peptide (AgRP) and neuropeptide Y (NPY). Conversely, in states of caloric deprivation, AgRP acts as a potent endogenous inverse agonist at MC4R, competitively displacing α-MSH and suppressing basal receptor signaling. Thus, α-MSH levels dictate the tonic signaling tone required to prevent overeating and maintain energy equilibrium.

The melanocortin rheostat hypothesis conceptualizes the melanocortin system not merely as an on-off binary switch, but as a finely tuned rheostatic dial controlling cellular inflammation and metabolism. Rather than acting as a traditional all-or-nothing immunosuppressant, α-MSH modulates leukocyte activation thresholds. By elevating cyclic AMP and stabilizing inhibitory proteins like IκBα, α-MSH ensures that tissue inflammatory responses do not progress into destructive immunopathology. This rheostatic buffering preserves organ integrity during infection and systemic stress.

Finally, the neuro-immuno-cutaneous axis framework posits that the skin is a fully functional neuroendocrine organ directly connected to the central nervous system. In this schema, keratinocytes, melanocytes, sensory nerve endings, and resident immune cells engage in bi-directional biochemical communication. Keratinocytes respond to cellular stressors by secreting α-MSH, which locally modulates melanogenesis, dampens cutaneous inflammation, and signals through local afferent fibers back to the central axis, exemplifying local endocrine autonomy.

7. Key Components, Types & Dimensions

Understanding α-MSH requires dissecting its biochemical isoforms, its active molecular domains, and its distinct receptor targets:

• Biochemical Isoforms & Processing Intermediates:
  • Desacetyl-α-MSH (ACTH_1–13-NH₂): The unacetylated precursor peptide; possesses substantial affinity for melanocortin receptors but undergoes faster enzymatic degradation in vivo.
  • Monoacetyl-α-MSH (Mature α-MSH): The fully modified, canonical tridecapeptide with an N-terminal acetyl group and C-terminal amide group, ensuring biological stability and peak receptor binding.
  • Diacetyl-α-MSH: An isoform bearing acetylation at both the N-terminal serine and the adjacent amino group; exhibits potent central anorexigenic and behavioral effects in specific mammalian brain regions.
• Functional Peptide Domains:
  • Active Pharmacophore (His⁶-Phe⁷-Arg⁸-Trp⁹): The invariant central sequence responsible for fitting directly into the binding pocket of melanocortin receptors and initiating intracellular G-protein signaling.
  • N-Terminal Anchor (Ser¹-Tyr²-Ser³-Met⁴-Glu⁵): Provides structural stabilization and optimizes pharmacological potency at target tissues.
  • C-Terminal Terminal Sequence (Gly¹⁰-Lys¹¹-Pro¹²-Val¹³-NH₂): Protects against exopeptidase degradation and contains message sequences essential for downstream anti-inflammatory effects.
• Target Receptor Profiles:
  • MC1R: Predominant in melanocytes and immune cells; directs cutaneous pigmentation, DNA repair mechanisms, and local anti-inflammatory actions.
  • MC3R: Concentrated in the central nervous system, gut, and macrophages; orchestrates nutrient partitioning, circadian metabolic rhythms, and macrophage resolution cascades.
  • MC4R: Highly expressed in hypothalamic nuclei; drives appetite suppression, energy expenditure, cardiovascular sympathetic tone, and erectile function.
  • MC5R: Found primarily in exocrine glands (including sebaceous glands); modulates exocrine lipid and pheromone production.

8. Examples & Illustrative Cases

The multifaceted roles of α-MSH can be illustrated through distinct clinical and biological scenarios:

Case 1: Congenital Pro-opiomelanocortin (POMC) Deficiency:
A pediatric patient presents in infancy with severe, intractable hyperphagia, rapid-onset obesity, pale skin, red hair (in individuals of European descent), and secondary adrenal insufficiency. Biochemical and genetic evaluation reveals a homozygous loss-of-function mutation in the POMC gene. Because the precursor peptide cannot be synthesized, the patient lacks both ACTH and α-MSH. The complete absence of hypothalamic α-MSH eliminates tonic MC4R activation, resulting in unremitting hunger and early childhood obesity, while the lack of cutaneous MC1R activation prevents eumelanin synthesis. Treatment with setmelanotide, a synthetic cyclic melanocortin-4 receptor agonist, successfully restores downstream MC4R signaling, curbs hyperphagia, and promotes weight normalization.

Case 2: Ultraviolet-Induced Melanogenesis (The Tanning Response):
Following solar ultraviolet B (UVB) exposure, cyclobutane pyrimidine dimers form within keratinocyte nuclear DNA. This genotoxic insult upregulates the tumor suppressor protein p53, which binds the POMC promoter in keratinocytes, driving local production and paracrine secretion of α-MSH. The released α-MSH binds MC1R on neighbouring melanocytes, activating the cAMP/PKA/MITF pathway. This elevates tyrosinase activity and increases the ratio of dark photoprotective eumelanin to pro-oxidant pheomelanin, producing a visible protective tan.

Case 3: Red Hair Color (MC1R Loss-of-Function Polymorphism):
An individual with pale, easily sunburned skin and red hair carries homozygous loss-of-function mutations (such as Arg151Cys or Arg160Trp) in the MC1R gene. Despite normal systemic levels of α-MSH released by keratinocytes upon sun exposure, the dysfunctional MC1R cannot signal via the cAMP pathway. Consequently, melanocytes fail to switch from pheomelanin to eumelanin synthesis, leaving the skin susceptible to ultraviolet-induced erythema and significantly elevating lifetime melanoma risk.

9. Measurement & Assessment

Assessing α-MSH levels presents distinct bioanalytical hurdles due to its picomolar circulating concentrations, rapid enzymatic degradation, and extensive sequence identity with ACTH.

In laboratory and clinical research, quantification relies on sensitive analytical platforms:

• Radioimmunoassay (RIA): Historically the primary technique for measuring peptide concentrations. Standard RIAs utilize polyclonal or monoclonal antibodies directed against synthetic α-MSH. However, these assays often cross-react with intact ACTH, ACTH_1–17, and desacetyl-α-MSH, requiring careful high-performance liquid chromatography (HPLC) pre-separation to yield accurate results.
• Enzyme-Linked Immunosorbent Assay (ELISA): Modern competitive commercial ELISA kits provide sensitive detection within serum, plasma, and cerebrospinal fluid (CSF). High-sensitivity ELISAs achieve detection thresholds as low as 1 to 5 pg/mL, though antibody cross-reactivity with post-translationally modified isoforms remains an analytical limitation.
• Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): Considered the gold standard for unambiguous identification and absolute quantification. LC-MS/MS distinguishes unmodified, monoacetylated, and diacetylated α-MSH variants based on unique mass-to-charge (m/z) ratios and collision fragmentation profiles, eliminating cross-reactivity with ACTH precursors.

Pre-analytical sample handling is vital. Because endogenous neutral endopeptidases (neprilysin) and aminopeptidases rapidly degrade α-MSH in biological fluids (plasma half-life is typically under five minutes), blood samples must be collected into chilled tubes containing EDTA and a protease inhibitor cocktail (such as aprotinin), separated via centrifugation at 4°C, and stored immediately at -80°C until analysis.

10. Applications & Practical Significance

Because α-MSH governs metabolic homeostasis, pigmentation, and inflammatory pathways, it has served as a blueprint for multiple therapeutic drugs:

Management of Monogenic and Syndromic Obesity:
The synthetic peptide analog setmelanotide is an FDA-approved MC4R agonist engineered to bypass deficient upstream hypothalamic POMC processing. Administered subcutaneously, setmelanotide activates MC4R directly, restoring satiety signaling and metabolic expenditure in individuals with POMC deficiency, PCSK1 deficiency, leptin receptor (LEPR) deficiency, and Bardet-Biedl syndrome.

Dermatological Photoprotection:
Afamelanotide, a synthetic tridecapeptide analog of α-MSH ([Nle⁴, D-Phe⁷]-α-MSH), exhibits extended pharmacological stability and high potency at MC1R. Formulated as a controlled-release subcutaneous implant, afamelanotide stimulates eumelanin synthesis independent of UV exposure. It is clinically indicated for photoprotection in patients with erythropoietic protoporphyria (EPP), shielding them from excruciating phototoxic skin reactions upon light exposure.

Treatment of Hypoactive Sexual Desire Disorder:
Bremelanotide, a cyclic heptapeptide analog derived from α-MSH, non-selectively stimulates central melanocortin receptors, primarily MC4R and MC3R. It cross-talks with central dopaminergic and noradrenergic pathways involved in sexual arousal and motivation. Administered as an autoinjector, bremelanotide is approved for premenopausal women suffering from generalized hypoactive sexual desire disorder (HSDD).

Anti-inflammatory and Ocular Therapeutics:
Preclinical and early-phase clinical trials continue to investigate α-MSH fragments and stable peptidomimetics (such as the C-terminal tripeptide KPV) for chronic inflammatory conditions, including inflammatory bowel disease, contact dermatitis, uveitis, and ischemia-reperfusion injuries, capitalizing on the peptide’s ability to silence NF-κB without the catabolic toxicities of traditional corticosteroids.

11. Research & Empirical Evidence

Decades of neurobiological and endocrinological research have cemented the critical role of α-MSH across mammalian organ systems. In 1997, seminal work by Daniel Huszar and colleagues demonstrated that mice harboring targeted disruptions of the MC4R gene developed severe, early-onset obesity accompanied by hyperphagia, hyperinsulinemia, and accelerated linear growth. Soon thereafter, studies led by Philippe Froguel and Stephen O’Rahilly established that heterozygous mutations in human MC4R represent the most common monogenic cause of severe human obesity, accounting for approximately 2% to 5% of early-onset extreme obesity cases worldwide.

Research into hypothalamic POMC circuitry has uncovered remarkable neuroplasticity. Seminal work by Michael Cowley and colleagues in 2001 revealed that circulating leptin directly depolarizes POMC neurons in the arcuate nucleus, increasing the frequency of action potentials and accelerating α-MSH exocytosis into synaptic junctions within the paraventricular nucleus. Concurrently, leptin hyperpolarizes and silences neighboring NPY/AgRP neurons, removing competitive antagonism at MC4R.

In immunology, research pioneered by J. Wayne Lipton and Thomas A. Luger demonstrated that α-MSH acts directly on peripheral leukocytes to inhibit lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines. Mechanistic studies confirmed that α-MSH blocks the degradation of IκB, preventing the p50/p65 heterodimer of NF-κB from translocating into the nucleus. Furthermore, α-MSH induces the generation of regulatory T cells (Tregs) in ocular tissues, establishing local immune privilege.

12. Cultural & Cross-Cultural Considerations

While the biochemical sequence of α-MSH is universal across modern humans, variation in its target receptor, MC1R, exhibits striking geographic and evolutionary diversity. As ancestral hominins migrated away from equatorial Africa into higher-latitude environments characterized by lower ambient ultraviolet radiation, selective pressure to maintain heavy eumelanic pigmentation relaxed.

Under relaxed selection and positive selection for lighter skin to allow cutaneous vitamin D synthesis under low-UV conditions, numerous loss-of-function alleles of the MC1R gene accumulated within European and Asian populations. Consequently, populations with northern European ancestry display high frequencies of MC1R variants, resulting in fair skin, red hair, and diminished tanning capacity in response to endogenous α-MSH. Conversely, populations originating from equatorial environments show profound evolutionary conservation of wild-type MC1R alleles, ensuring strong melanogenic responses to protect against UV-induced folate photolysis and cutaneous malignancy.

These biological variations also shape contemporary public health discussions concerning sunbeds, synthetic tanning injections, and tanning culture. Unregulated illicit markets for “Melanotan-II”—an unapproved synthetic α-MSH mimetic self-injected for cosmetic skin tanning and sexual stimulation—present ongoing challenges for public health authorities globally due to systemic side effects like severe hypertension, nausea, and atypical melanocytic nevi.

13. Criticisms, Debates & Limitations

Despite extensive study, therapeutic exploitation of the α-MSH signaling axis has encountered substantial scientific and clinical hurdles:

Cardiovascular and Pressor Effects:
A primary challenge in developing central MC4R agonists for obesity has been off-target cardiovascular activation. Activation of MC4R in the autonomic nervous system triggers sympathetic outflow to the kidneys and heart, leading to elevated blood pressure and tachycardia. Early drug candidates like sibutramine and initial small-molecule MC4R agonists were abandoned during clinical development due to hypertension. While setmelanotide avoids this liability through biased downstream signaling, off-target hemodynamic effects remain a central concern in melanocortin pharmacology.

Blood-Brain Barrier Penetration and Pharmacokinetics:
Endogenous α-MSH has a biological half-life measured in minutes, making native peptide administration therapeutically impractical. Because native α-MSH does not readily cross the intact blood-brain barrier, treating hypothalamic dysfunctions requires structural cyclization, non-natural amino acid substitutions, or lipid conjugations to allow central penetration.

Receptor Subtype Cross-Reactivity:
Because the active pharmacophore (His-Phe-Arg-Trp) is conserved across melanocortin receptors, designing molecules that selectively bind one receptor subtype without triggering unwanted secondary effects (such as skin hyperpigmentation via MC1R, spontaneous erections via central MC4R, or sebaceous stimulation via MC5R) requires complex structural chemistry.

14. Related Terms & Distinctions

The following peptides and molecules are closely linked with α-MSH but maintain distinct physiological profiles:

• Adrenocorticotropic Hormone (ACTH): A 39-amino-acid peptide derived from the same POMC precursor. While ACTH contains the exact sequence of α-MSH within its first 13 amino acids, it acts primarily at MC2R in the adrenal cortex to stimulate glucocorticoid synthesis, whereas α-MSH cannot activate MC2R.
• Agouti-Related Peptide (AgRP): An endogenous 112-amino-acid neuropeptide co-expressed with NPY in the arcuate nucleus. AgRP acts as a competitive antagonist and inverse agonist at MC3R and MC4R, directly opposing the appetite-suppressing actions of α-MSH.
• Beta-MSH (β-MSH) and Gamma-MSH (γ-MSH): Alternative cleavage products of POMC. Beta-MSH binds MC4R to influence energy balance, while gamma-MSH selectively binds MC3R, playing a specialized role in sodium balance, blood pressure control, and cardiovascular reflexes.
• Setmelanotide: A synthetic, cyclic 8-amino-acid peptide agonist engineered to selectively stimulate MC4R, used to treat severe monogenic obesity disorders caused by upstream defects in α-MSH synthesis.
• Afamelanotide: A synthetic analog ([Nle⁴, D-Phe⁷]-α-MSH) with prolonged half-life and elevated potency at MC1R, utilized clinically to stimulate photoprotective melanin in patients with erythropoietic protoporphyria.

15. Summary / Key Takeaways

Alpha-melanocyte-stimulating hormone (α-MSH) is an essential tridecapeptide derived from POMC that coordinates energy homeostasis, pigmentation, and inflammatory resolution across the mammalian body. Operating centrally through MC4R, it delivers powerful catabolic satiety signals, protecting against obesity. Peripherally, it acts via MC1R to drive photoprotective eumelanin synthesis within melanocytes and suppresses destructive inflammatory pathways across immune cells. Its actions are counterbalanced by endogenous inverse agonists like AgRP, maintaining tight homeostatic equilibrium. Ongoing translational research into synthetic α-MSH analogs has yielded clinically approved therapies for rare monogenic obesity, photodermatoses, and hypoactive sexual desire disorder, cementing its importance across modern pharmacology and endocrinology.

References

• Cone, R. D. (2006). Studies on the melanocortin system: An overview. Peptides, 27(2), 187–192. https://pubmed.ncbi.nlm.nih.gov/16377034/
• Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001). Leptin activates anorexigenic POMC neurons through a depolarization that involves TRPC-like channels. Nature, 411(6836), 480–484. https://pubmed.ncbi.nlm.nih.gov/11373681/
• Catania, A., Gatti, S., Colombo, G., & Lipton, J. M. (2004). Targeting melanocortin receptors as a novel strategy in neuroimmunomodulation. Pharmacological Reviews, 56(1), 1–29. https://pubmed.ncbi.nlm.nih.gov/15001661/
• D’Orazio, J., Jarrett, S., Amaro-Ortiz, A., & Scott, T. (2013). UV radiation and the skin. International Journal of Molecular Sciences, 14(6), 12222–12248. https://pubmed.ncbi.nlm.nih.gov/23749111/
• Yeo, G. S. H., Chao, D. H. M., Siegert, A. M., Koerperich, Z. M., Ericson, M. D., Simonds, S. E., Larson, C. M., Luquet, S., Clarke, I., & Cowley, M. A. (2021). The melanocortin-4 receptor: Physiology, pharmacology, and therapeutic prospects. Endocrine Reviews, 42(5), 606–644. https://pubmed.ncbi.nlm.nih.gov/33693636/